Early Experience of Oncolytic Virus Injection Combined with Sorafenib in a Patient with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis
Journal of Liver Cancer
;
: 177-182, 2020.
Artigo
| WPRIM
| ID: wpr-836098
ABSTRACT
JX-594 is a modified oncolytic poxvirus designed to selectively replicate in and destroy cancer cells. In a pilot study, JX-594 injection followed by sorafenib was well-tolerated in three patients and associated with objective tumor responses. In this study, we report a case in which a patient with advanced hepatocellular carcinoma and portal vein thrombosis was treated with a combination of JX-594 and sorafenib.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Revista:
Journal of Liver Cancer
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS